GCP-Service International Ltd. & Co. KG   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Bremen Germany (2004)

Organization Overview

First Clinical Trial
2014
NCT02278718
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

GCP ClinPlus Co., Ltd. | GCP-Service International Ltd. & Co. KG | GCP-Service International s.r.o. | GCP-Service International West GmbH | GCP services

Active Ingredients

Drugs in Phase 4 Trials (3)

aminolevulinic acid (levulan) (1 trial)

budesonide (rhinocort) (1 trial)

estriol (1 trial)

Drugs in Phase 3 Trials (1)

anacaulase (NexoBrid) (1 trial)

Drugs in Phase 2 Trials (3)

autologous muscle derived stem cells (1 trial)

Imetelstat (1 trial)

nivolumab (opdivo) (1 trial)

Drugs in Phase 1 Trials (2)

gem333 (1 trial)

gem3psca (1 trial)

Drugs in Other Trials (1)

orelabrutinib (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Atrophy (Phase 4)

Burns (Phase 3)

Keratosis (Phase 4)

Keratosis, Actinic (Phase 4)

Leukemia (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Urogenital Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial APIs: 10